Overview: West Nile IgG TestIntroduction: The West Nile IgG Test detects West Nile virus IgG to confirm past infection, preventing neurological issues. Following 2023 CDC guidelines, it uses immunoassays for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected past West Nile virus exposure. Note: Test Parameters are not specified in input data; typically includes West Nile virus IgG antibodies.
Other Names: West Nile IgG Assay, WNV Immunity Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: West Nile IgG testing began in the 2000s with arbovirus research. Immunoassay methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Detects West Nile IgG to confirm past infection, guides preventive measures, and evaluates patients with neurological concerns.
Test Parameters: Not specified in input data; typically includes West Nile virus IgG antibodies.
Pretest Condition: No fasting required. Collect serum or saliva. Report history of neurological symptoms or West Nile virus exposure.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document neurological symptoms, fever, or history of West Nile virus exposure. Include current medications or travel history.
Consent: Written consent required, detailing the tests purpose, West Nile virus implications, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect West Nile IgG antibodies. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for past infection assessment.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other flaviviruses may reduce specificity.
Clinical Significance: Positive West Nile IgG confirms past infection, guiding neurological monitoring or public health reporting. Negative results may require IgM or PCR testing.
Specialist Consultation: Consult an infectious disease specialist or neurologist for result interpretation and management.
Additional Supporting Tests: West Nile IgM, PCR, or neurological imaging to assess current or past infection status.
Test Limitations: Non-specific for active infection; clinical correlation is needed. Sample quality affects sensitivity.
References: CDC West Nile Virus Guidelines, 2023; Clinical Infectious Diseases, Petersen LR, 2022.
